Price L H, Malison R T, McDougle C J, Pelton G H
Clinical Neuroscience Research Unit, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, and Department of Psychiatry, Yale University School of Medicine, 34 Park St, New Haven, Connecticut, 06519, USA.
CNS Drugs. 1996 May;5(5):311-20. doi: 10.2165/00023210-199605050-00001.
There is considerable interest in the possible antidepressant properties of antiglucocorticoids. Studies of the hypothalamic-pituitary-adrenal (HPA) axis in depression, coupled with increasing recognition of the importance of glucocorticoids in brain function, strongly support such interest.Psychiatric symptomatology in Cushing's syndrome (a disorder involving hypersecretion of cortisol), the adverse cognitive effects of glucocorticoids, and the suppressive effects of conventional antidepressants on HPA function all suggest that HPA abnormalities could cause or contribute to depression. However, the psychiatrie effects of glucocortieoids and glucocorticoid withdrawal suggest that HPA hyperactivity compensates for some other defect. While preliminary clinical studies suggest that both glucocorticoids and antiglucocorticoids may have efficacy in depression, the toxicity and loss of efficacy of available drugs during long term administration will probably necessitate the development of new agents to advance this field.
抗糖皮质激素可能具有的抗抑郁特性引发了人们相当大的兴趣。对抑郁症患者下丘脑-垂体-肾上腺(HPA)轴的研究,以及对糖皮质激素在脑功能中重要性的认识不断增加,有力地支持了这种兴趣。库欣综合征(一种涉及皮质醇分泌过多的疾病)中的精神症状、糖皮质激素的不良认知影响以及传统抗抑郁药对HPA功能的抑制作用,都表明HPA异常可能导致或促成抑郁症。然而,糖皮质激素和糖皮质激素戒断的精神效应表明,HPA功能亢进是对其他某种缺陷的一种代偿。虽然初步临床研究表明糖皮质激素和抗糖皮质激素在抑郁症中可能都有效,但现有药物在长期给药过程中的毒性和疗效丧失可能需要开发新的药物来推动这一领域的发展。